Definitive Healthcare’s (DH) Underweight Rating Reaffirmed at Barclays

Barclays reiterated their underweight rating on shares of Definitive Healthcare (NASDAQ:DH) in a report released on Monday, MarketBeat.com reports. The brokerage currently has a $4.00 price objective on the stock.

Several other equities analysts have also recently weighed in on the company. Stephens assumed coverage on Definitive Healthcare in a report on Friday, December 20th. They set an “equal weight” rating and a $5.00 price target on the stock. BTIG Research assumed coverage on Definitive Healthcare in a research note on Tuesday, September 17th. They issued a “buy” rating and a $7.00 price objective for the company. Finally, Needham & Company LLC restated a “hold” rating on shares of Definitive Healthcare in a research note on Friday, November 8th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Definitive Healthcare has a consensus rating of “Hold” and a consensus target price of $5.72.

Definitive Healthcare Price Performance

NASDAQ DH opened at $3.93 on Monday. The business’s fifty day moving average price is $4.37 and its 200-day moving average price is $4.52. The stock has a market capitalization of $453.99 million, a price-to-earnings ratio of -1.27, a PEG ratio of 3.14 and a beta of 1.40. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49. Definitive Healthcare has a 1-year low of $3.19 and a 1-year high of $10.62.

Insiders Place Their Bets

In other Definitive Healthcare news, insider William Moschella sold 45,000 shares of the stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $4.70, for a total transaction of $211,500.00. Following the completion of the transaction, the insider now owns 433,830 shares of the company’s stock, valued at $2,039,001. This represents a 9.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 14.84% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in DH. Principal Financial Group Inc. lifted its holdings in shares of Definitive Healthcare by 10.8% in the 2nd quarter. Principal Financial Group Inc. now owns 39,856 shares of the company’s stock valued at $218,000 after acquiring an additional 3,874 shares during the last quarter. Rhumbline Advisers lifted its stake in Definitive Healthcare by 19.7% in the second quarter. Rhumbline Advisers now owns 83,751 shares of the company’s stock worth $457,000 after purchasing an additional 13,764 shares during the last quarter. Victory Capital Management Inc. lifted its stake in Definitive Healthcare by 1.9% in the second quarter. Victory Capital Management Inc. now owns 509,009 shares of the company’s stock worth $2,779,000 after purchasing an additional 9,316 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Definitive Healthcare by 28.3% in the second quarter. Massachusetts Financial Services Co. MA now owns 4,426,420 shares of the company’s stock worth $24,168,000 after purchasing an additional 976,279 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Definitive Healthcare by 50.5% in the second quarter. Renaissance Technologies LLC now owns 28,900 shares of the company’s stock worth $158,000 after purchasing an additional 9,700 shares during the last quarter. Institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.